Effentora

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

fentanyl

Disponible depuis:

Teva B.V.

Code ATC:

N02AB03

DCI (Dénomination commune internationale):

fentanyl

Groupe thérapeutique:

Analgesics

Domaine thérapeutique:

Pain; Cancer

indications thérapeutiques:

Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. ,

Descriptif du produit:

Revision: 28

Statut de autorisation:

Authorised

Date de l'autorisation:

2008-04-04

Notice patient

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
EFFENTORA 100 MICROGRAMS BUCCAL TABLETS
EFFENTORA 200 MICROGRAMS BUCCAL TABLETS
EFFENTORA 400 MICROGRAMS BUCCAL TABLETS
EFFENTORA 600 MICROGRAMS BUCCAL TABLETS
EFFENTORA 800 MICROGRAMS BUCCAL TABLETS
Fentanyl
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Effentora is and what it is used for
2.
What you need to knowbefore you use Effentora
3.
How to use Effentora
4.
Possible side effects
5.
How to store Effentora
6.
Contents of the pack and other information
1.
WHAT EFFENTORA IS AND WHAT IT IS USED FOR
The active substance of Effentora is fentanyl citrate. Effentora is a
pain-relieving medicine known as
an opioid, which is used to treat breakthrough pain in adult patients
with cancer who are already taking
other opioid pain medicines for their persistent (around-the-clock)
cancer pain.
Breakthrough pain is additional, sudden pain that occurs in spite of
you having taken your usual opioid
pain-relieving medicines.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE EFFENTORA
DO NOT USE EFFENTORA:
•
If you are not regularly using a prescribed opioid medicine (e.g
codeine, fentanyl, hydromorphone,
morphine, oxycodone, pethidine), every day on a regular schedule, for
at least a week, to control
your persistent pain. If you have not been using these medicines you MUST NOT
use Effentora,
because it may increase the risk that breathing could become
dangerously slow and/or shallow, or
even stop.
•
If you are allergic to fentanyl or any of the ot
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Effentora 100 micrograms buccal tablets
Effentora 200 micrograms buccal tablets
Effentora 400 micrograms buccal tablets
Effentora 600 micrograms buccal tablets
Effentora 800 micrograms buccal tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Effentora 100 micrograms buccal tablets
Each buccal tablet contains 100 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 10 mg of sodium.
Effentora 200 micrograms buccal tablets
Each buccal tablet contains 200 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 20 mg of sodium.
Effentora 400 micrograms buccal tablets
Each buccal tablet contains 400 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 20 mg of sodium.
Effentora 600 micrograms buccal tablets
Each buccal tablet contains 600 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 20 mg of sodium.
Effentora 800 micrograms buccal tablets
Each buccal tablet contains 800 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 20 mg of sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Buccal tablet.
Effentora 100 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on the other side
with “1”.
Effentora 200 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on the other side
with “2”.
Effentora 400 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on the other side
with “4”.
Effentora 600 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on the other side
with “6”.
3
Effentora 800 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation bulgare 14-04-2014
Notice patient Notice patient espagnol 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation espagnol 14-04-2014
Notice patient Notice patient tchèque 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation tchèque 14-04-2014
Notice patient Notice patient danois 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation danois 14-04-2014
Notice patient Notice patient allemand 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation allemand 14-04-2014
Notice patient Notice patient estonien 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation estonien 14-04-2014
Notice patient Notice patient grec 04-04-2024
Notice patient Notice patient français 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation français 14-04-2014
Notice patient Notice patient italien 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation italien 14-04-2014
Notice patient Notice patient letton 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation letton 14-04-2014
Notice patient Notice patient lituanien 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation lituanien 14-04-2014
Notice patient Notice patient hongrois 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation hongrois 14-04-2014
Notice patient Notice patient maltais 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation maltais 14-04-2014
Notice patient Notice patient néerlandais 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation néerlandais 14-04-2014
Notice patient Notice patient polonais 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation polonais 14-04-2014
Notice patient Notice patient portugais 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation portugais 14-04-2014
Notice patient Notice patient roumain 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation roumain 14-04-2014
Notice patient Notice patient slovaque 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation slovaque 14-04-2014
Notice patient Notice patient slovène 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation slovène 14-04-2014
Notice patient Notice patient finnois 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation finnois 14-04-2014
Notice patient Notice patient suédois 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation suédois 14-04-2014
Notice patient Notice patient norvégien 04-04-2024
Notice patient Notice patient islandais 04-04-2024
Notice patient Notice patient croate 04-04-2024
Rapport public d'évaluation Rapport public d'évaluation croate 14-04-2014

Rechercher des alertes liées à ce produit

Afficher l'historique des documents